PL2437749T3 - Naprzemienny sposób leczenia nowotworu lub stanu przednowotworowego - Google Patents

Naprzemienny sposób leczenia nowotworu lub stanu przednowotworowego

Info

Publication number
PL2437749T3
PL2437749T3 PL10784166T PL10784166T PL2437749T3 PL 2437749 T3 PL2437749 T3 PL 2437749T3 PL 10784166 T PL10784166 T PL 10784166T PL 10784166 T PL10784166 T PL 10784166T PL 2437749 T3 PL2437749 T3 PL 2437749T3
Authority
PL
Poland
Prior art keywords
treating cancer
precancerous condition
interlaced method
interlaced
precancerous
Prior art date
Application number
PL10784166T
Other languages
English (en)
Polish (pl)
Inventor
Andrew J. Krouse
Lloyd S. Gray
Timothy Macdonald
Joel Linden
Original Assignee
Cavion, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cavion, Inc. filed Critical Cavion, Inc.
Publication of PL2437749T3 publication Critical patent/PL2437749T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL10784166T 2009-06-05 2010-06-04 Naprzemienny sposób leczenia nowotworu lub stanu przednowotworowego PL2437749T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18465809P 2009-06-05 2009-06-05
EP10784166.0A EP2437749B8 (en) 2009-06-05 2010-06-04 Interlaced method for treating cancer or a precancerous condition
PCT/US2010/037437 WO2010141842A2 (en) 2009-06-05 2010-06-04 Interlaced method for treating cancer or a precancerous condition

Publications (1)

Publication Number Publication Date
PL2437749T3 true PL2437749T3 (pl) 2018-04-30

Family

ID=43298556

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10784166T PL2437749T3 (pl) 2009-06-05 2010-06-04 Naprzemienny sposób leczenia nowotworu lub stanu przednowotworowego

Country Status (15)

Country Link
US (2) US20120088807A1 (enExample)
EP (1) EP2437749B8 (enExample)
JP (2) JP5806210B2 (enExample)
KR (2) KR20120030112A (enExample)
CN (2) CN106177963A (enExample)
AU (1) AU2010256442B2 (enExample)
CA (1) CA2764499A1 (enExample)
DK (1) DK2437749T3 (enExample)
ES (1) ES2661216T3 (enExample)
IL (2) IL216443A (enExample)
MX (1) MX344725B (enExample)
PL (1) PL2437749T3 (enExample)
SG (3) SG176678A1 (enExample)
WO (1) WO2010141842A2 (enExample)
ZA (1) ZA201108909B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102781316B (zh) 2010-03-01 2016-07-06 陶制药有限责任公司 癌症诊断和成像
EP2755674A4 (en) * 2011-09-12 2015-04-08 Tau Therapeutics Llc ANTAGONISTS OF PRODUCTS OF THE HS-459642-UNIGEN CLUSTER TO AVOID PROLIFERATION, DEVELOPMENT, OR DIFFERENTIATION OF STEM CELLS WITH CANCER STEM CELLS
US11642353B2 (en) 2014-02-06 2023-05-09 The Procter & Gamble Company Hair care composition comprising antidandruff agent and polyquaternium-6
US11058624B2 (en) 2014-02-06 2021-07-13 The Procter And Gamble Company Hair care composition comprising cationic polymers and anionic particulates
EP3364993B1 (en) 2015-10-22 2022-11-09 Cavion, Inc. Methods for treating angelman syndrome
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN110545806A (zh) 2017-02-15 2019-12-06 卡维昂公司 钙通道抑制剂
EP3615521A4 (en) 2017-04-26 2021-02-17 Cavion, Inc. METHODS FOR IMPROVING MEMORY AND COGNITION AND TREATING MEMORY AND COGNITIVE DISORDERS
JP7480131B2 (ja) 2018-10-03 2024-05-09 カビオン・インコーポレイテッド （ｒ）－２－（４－イソプロピルフェニル）－ｎ－（１－（５－（２，２，２－トリフルオロエトキシ）ピリジン－２－イル）エチル）アセトアミドを使用した本態性振戦の処置
CN118217178A (zh) 2018-10-04 2024-06-21 宝洁公司 包含水不溶性固体有机化合物的个人护理组合物
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251886B1 (en) * 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20060003020A1 (en) * 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
TW200538149A (en) * 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
US20060000320A1 (en) * 2004-06-30 2006-01-05 Hutton William M Ratchet wrench tool assembly for underground work and process of using
CA2576186A1 (en) * 2004-08-20 2006-03-02 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
CA2576191C (en) * 2004-08-20 2013-03-19 University Of Virginia Patent Foundation T type calcium channel inhibitors
CN100546579C (zh) * 2006-12-30 2009-10-07 南京工业大学 替莫唑胺聚乳酸纳米微球与制剂及其制备方法
WO2008141189A1 (en) * 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof

Also Published As

Publication number Publication date
JP5806210B2 (ja) 2015-11-10
SG10201402863PA (en) 2014-10-30
WO2010141842A2 (en) 2010-12-09
SG176678A1 (en) 2012-01-30
CN106177963A (zh) 2016-12-07
DK2437749T3 (da) 2018-01-29
ES2661216T3 (es) 2018-03-28
EP2437749A2 (en) 2012-04-11
MX344725B (es) 2017-01-05
EP2437749B8 (en) 2018-02-21
IL216443A (en) 2016-11-30
CN102458416A (zh) 2012-05-16
EP2437749B1 (en) 2017-12-20
KR20120030112A (ko) 2012-03-27
WO2010141842A3 (en) 2011-04-21
US20120088807A1 (en) 2012-04-12
JP2016028058A (ja) 2016-02-25
KR101905050B1 (ko) 2018-10-08
SG10201810806UA (en) 2019-01-30
MX2011012940A (es) 2012-04-20
EP2437749A4 (en) 2013-04-17
IL248482A0 (en) 2016-12-29
JP6159958B2 (ja) 2017-07-12
US20180228822A1 (en) 2018-08-16
ZA201108909B (en) 2013-02-27
JP2012528890A (ja) 2012-11-15
AU2010256442A1 (en) 2012-01-19
KR20170097237A (ko) 2017-08-25
CA2764499A1 (en) 2010-12-09
AU2010256442B2 (en) 2016-07-21
IL216443A0 (en) 2012-02-29
IL248482B (en) 2020-08-31

Similar Documents

Publication Publication Date Title
IL248482A0 (en) A combined method for treating cancer or a pre-cancerous condition
GB0905140D0 (en) Method
GB0911905D0 (en) Method
GB0902476D0 (en) Method
GB0910707D0 (en) Method
GB0913525D0 (en) Method
GB0810566D0 (en) Co-existence method
GB0913433D0 (en) Method
GB0901444D0 (en) Method
GB0903316D0 (en) Method
GB0905367D0 (en) Method
GB0908770D0 (en) Method
GB0902034D0 (en) Method
GB0911362D0 (en) Method
GB0904946D0 (en) Method
GB0900560D0 (en) Method
GB0914702D0 (en) Method
GB0908816D0 (en) Method
GB0905332D0 (en) Method
GB2475133B (en) Security apparatus
GB0914318D0 (en) Method
GB0911717D0 (en) Method
GB2483039B (en) Method for treating hydrocarbons
GB0903495D0 (en) Improved methods for identification
GB0920887D0 (en) Barrier Apparatus